News & Analysis on Clinical Trial Services & Contract Research And Development
Ranbaxy’s CEO has confidently asserted that the US Food and Drug Administration’s (FDA) court action will be dropped in the near future and fired another warning shot at the “negative elements” he believes were behind the controversy.
FDA officials have impounded nearly $24m (€15.4m) worth of guaifenesin-containing timed-release (TR) cough and cold medicines made by US specialty drugmaker KV Pharmaceuticals.
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.